Caries in deciduous teeth (change in dmft) · Children and adolescents aged 16 years or less
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Chlorhexidine showed no clear difference in oral mucositis (severe) compared with cryotherapy (ice chips); GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Chinese herbs (medicine) showed no clear difference in oral mucositis (severe) compared with control (Dobell's solution); GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
G-CSF led to lower oral mucositis (severe) compared with placebo/no treatment; GRADE not reported.
1 finding from 1 review
RR 0.36 [0.15, 0.86]
2 studies
GRADE not reported
Time to complete healing · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Two studies. Median time to total healing was shorter for patients receiving oral or intravenous aciclovir than placebo: median of 8 days versus 21 days, P = 0.01 (Shepp 1985); 13.9 days versus 20.7 days, P = 0.08…
2 studies
GRADE not reported
Recurrence of lesions · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Duration of viral shedding · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Relief of pain · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Length of hospital stay · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Amount of analgesia · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Viral isolates · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)
1 finding from 1 review
Orlowski 2004: 182 throat swabs performed for patients receiving 500 mg of valaciclovir (n = 40) and 198 swabs for those receiving 1000 mg (n = 41); all of the cultures proved negative (1 trial, 81; not estimable).
1 study · 81 participants
GRADE not reported
Patient quality of life · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Adverse effects · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)
1 finding from 1 review
One study reported adverse effects (Warkentin 2002). Twenty patients allocated to receive high dose valaciclovir reported adverse effects (42%); for the low dose group this number was 27 (52%). Adverse effects were…
1 study · 100 participants
GRADE not reported
Adverse effects · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Cost of oral care · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Viral isolates · Patients being treated for cancer (leukaemia)
Prophylactic prostaglandin E (oral) led to higher viral isolates compared with placebo; GRADE not reported.
1 finding from 1 review
Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs partially absorbed from GI tract (miconazole,… showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Empirical antifungal treatment · Patients with cancer receiving chemotherapy and/or radiotherapy
Itraconazole showed no clear difference in empirical antifungal treatment compared with fluconazole; GRADE not reported.
1 finding from 1 review
Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Relief of dysphagia · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review